Nautilus Biotechnology Inc (NAUT) stock shows 52-week fluctuation between $0.62 and $2.67

Nora Barnes

At the time of writing, Nautilus Biotechnology Inc [NAUT] stock is trading at $1.66, saw in change for the day. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NAUT shares have gain 4.40% over the last week, with a monthly amount glided 86.71%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Nautilus Biotechnology Inc [NASDAQ: NAUT] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1.75 for it. Previously, Guggenheim started tracking the stock with Buy rating on June 27, 2024, and set its price target to $6. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $8 on January 06, 2022. Cowen initiated its recommendation with a Outperform. Goldman started tracking with a Neutral rating for this stock on August 04, 2021, and assigned it a price target of $10. In a note dated July 13, 2021, Jefferies initiated a Buy rating and provided a target price of $13 on this stock.

For the past year, the stock price of Nautilus Biotechnology Inc fluctuated between $0.62 and $2.67. Currently, Wall Street analysts expect the stock to reach $2.5 within the next 12 months. Nautilus Biotechnology Inc [NASDAQ: NAUT] shares were valued at $1.66 at the most recent close of the market. An investor can expect a potential return of 50.6% based on the average NAUT price forecast.

Analyzing the NAUT fundamentals

Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -7.44%, Pretax Profit Margin comes in at -6.54%, and Net Profit Margin reading is -6.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.33 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5967 points at the first support level, and at 1.5333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7317, and for the 2nd resistance point, it is at 1.8033.

Ratios To Look Out For

It is important to note that Nautilus Biotechnology Inc [NASDAQ:NAUT] has a current ratio of 14.95. Further, the Quick Ratio stands at 14.95, while the Cash Ratio is 2.66.

Transactions by insiders

Recent insider trading involved Suzuki Kentaro, Chief Marketing Officer, that happened on Nov 06 ’25 when 4000.0 shares were purchased. CEO, President, and Secretary, Patel Sujal M completed a deal on Sep 05 ’25 to buy 0.12 million shares. Meanwhile, CEO, President, and Secretary Patel Sujal M bought 83500.0 shares on Sep 08 ’25.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.